The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 319.50
Bid: 318.00
Ask: 320.00
Change: -0.50 (-0.16%)
Spread: 2.00 (0.629%)
Open: 324.00
High: 324.00
Low: 319.50
Prev. Close: 320.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 flat as Vodafone loss offsets gains in banks; Oxford Biomedica shines

Tue, 18th May 2021 09:23

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Oxford Biomedica rises on robust outlook

* Vodafone drops after missing earnings expectations

* FTSE 100 up 0.2%, FTSE 250 adds 0.6%
(Updates with market close)

By Shivani Kumaresan and Devik Jain

May 18 (Reuters) - London's FTSE 100 was little changed on
Tuesday as poor earnings by Vodafone offset gains in bank
stocks, while better-than-expected jobs data strengthened views
of a stronger economic recovery from a pandemic-driven crash
last year.

The blue-chip index rose 0.02%, with banks, mainly
HSBC Holdings, Lloyds Banking Group and
Standard Chartered gaining between 0.8% and 1.5%.

Consumer discretionary stocks, including Compass Group
, Kingfisher and Just Eat Takeaway.com
also provided the biggest boost to the index.

Mobile operator Vodafone Group fell 8.9% on
reporting a 1.2% drop in annual adjusted earnings, as COVID-19
hit roaming revenue and handset sales.

The domestically focussed mid-cap FTSE 250 index
climbed 0.5%.

Britain's unemployment rate fell again, to 4.8% between
January and March, and hiring rose further in April, according
to data that showed employers gearing up for the easing of
coronavirus curbs.

"A third consecutive month of falling unemployment suggests
the peak rate caused by the pandemic wasn't as high as feared",
said Sophie Griffiths, Market Analyst, UK & EMEA at OANDA.

"While the furlough scheme has succeeded in preventing a
wave of redundancies, there is little doubt the jobless rate
will rise again when it concludes in September."

Britain extended its huge job-protecting furlough programme
by five months until the end of September, covering about one in
five private-sector employees who receive 80% of their salary
for hours not worked.

The FTSE 100 has gained nearly 9.4% year-to-date as
investors flocked to energy, materials and banking stocks that
are seen benefiting the most from a stronger economic recovery
due to speedy COVID-19 vaccinations and government support.

Fund managers loaded up on UK stocks and cut exposure to
technology stocks as rising inflation and "taper tantrum" fears
leave growth stocks vulnerable to pull-backs, Bank of America's
May fund manager survey released on Tuesday found.

Among other stocks, Oxford Biomedica gained 10.4%,
to the top of the mid-cap index after it doubled the revenue
expectation from its COVID-19 vaccine supply deal with drugmaker
AstraZeneca.

Imperial Brands rose 1.5% after the tobacco company
reiterated its full-year outlook.
(Reporting by Shivani Kumaresan and Devik Jain in Bengaluru;
editing by Uttaresh.V and Jonathan Oatis)

More News
1 Dec 2020 14:29

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

Read more
9 Nov 2020 10:01

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Read more
9 Nov 2020 09:16

Oxford Biomedica strikes collaboration agreement with PhoreMost

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.

Read more
4 Nov 2020 09:40

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

Read more
30 Oct 2020 08:47

Oxford Biomedica partner delays Parkinson's disease treatment trial

(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.

Read more
23 Oct 2020 15:15

UK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million

UK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million

Read more
6 Oct 2020 14:19

Oxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD

Oxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD

Read more
6 Oct 2020 09:44

Another Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval

Another Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval

Read more
6 Oct 2020 07:55

LONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development

LONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development

Read more
6 Oct 2020 07:43

LONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance

LONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance

Read more
6 Oct 2020 07:03

Oxford Biomedica new manufacturing suite approved

(Sharecast News) - Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.

Read more
17 Sep 2020 10:43

Oxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal

Oxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal

Read more
17 Sep 2020 08:35

LONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE

LONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE

Read more
17 Sep 2020 07:52

LONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook

LONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook

Read more
17 Sep 2020 07:01

Oxford Biomedica sees swing to FY profit on Covid vaccine hopes

(Sharecast News) - Drugs maker Oxford Biomedica, which has partnered with pharma giant AstraZeneca to develop a Covid-19 vaccine, said it expected higher second half revenues to push it to a low-to-single digit full year profit.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.